Clinical Trial Update: Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating neoadjuvant short-course radiotherapy followed by a combination of disitamab vedotin, sintilimab, and capecitabine for locally advanced…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Disitamab Vedotin (disitamab vedotin)
• Sintilimab (sintilimab)

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Rectal Cancer | Phase 2 | Status: NOT_YET_RECRUITING